Lixte Announces Further Developments Regarding the Anti-Cancer Activity of its Patent-Pending Proprietary Compounds
News Mar 03, 2008
Lixte Biotechnology Holdings, Inc. and its collaborator, the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), reported at the 1st International Conference on Drug Discovery and Development, Dubai, UAE, February 6, 2008, that its lead compound LB-1, one of a patent-pending proprietary series of agents, has anti-cancer activity against medulloblastoma cells growing in culture and in a mouse model of cancer. Medulloblastoma is the most common brain tumor of children and is often fatal.
Dr. John S. Kovach, the lead presenter and President and CEO of Lixte, said that the company and SNB, NINDS are continuing to develop LB-1 and other compounds for the treatment of human brain cancers. Brain cancers pose a particular challenge to the development of effective drug treatments.
The brain is protected by a physiological barrier which prevents the entry of most potentially effective therapeutic agents. To be effective, drugs must be designed either to pass this barrier or to be administered directly into the brain. "Lixte is pursuing both strategies to deliver its lead compounds to brain cancers," said Dr. Kovach.
In other studies done by Lixte independently of NIH, Dr. Kovach commented, "That LB-1 and other lead compounds have also been found to have anti-cancer activity against a broad range of common human cancers growing in cell culture. The effectiveness of these compounds will now be determined in mouse models of human cancer, starting with lung and pancreatic cancer."
In addition, Dr. Kovach said that, "Some of Lixte's compounds have been shown to have anti-fungal activity. We have found that LB-2.1 and other drugs in a second series of patent-pending proprietary compounds inhibit the growth of several types of fungi that cause life-threatening infections in immuno- compromised patients, such as those with HIV-AIDS or undergoing bone marrow transplantation. Given this lead, Lixte is initiating studies to assess the potential value of these compounds for treatment of serious fungal diseases."
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE